Can I breastfeed during a ketamine course?

This is a question for your OB and your pediatrician, not a question we answer unilaterally. Milk-transfer data for ketamine is limited. Many clinics use a pump-and-discard window of roughly 12 to 24 hours after each infusion, but the right approach depends on your dose, your baby's age, and feeding plan. We will not start treatment without that coordinated plan.

What about during pregnancy?

Generally no. We treat pregnancy as a separate, higher-caution conversation, and we defer to OB and perinatal psychiatry. We have a dedicated article on ketamine during pregnancy and breastfeeding that walks through the considerations. The short version is that ketamine is not a first-line option in pregnancy and we will not proceed without OB sign-off.

What if my anxiety is keeping me from sleeping?

Sleep deprivation in early postpartum is a separate problem that often masquerades as anxiety. Before considering ketamine, address protected sleep blocks, partner or family support, and screening for postpartum depression. Many women see meaningful improvement in postpartum anxiety symptoms once sleep stabilizes. If anxiety persists after sleep is addressed and first-line treatments have been tried, that is the conversation to have with your OB.

Is postpartum anxiety different from postpartum depression?

Yes. Postpartum anxiety is dominated by intrusive worry, hypervigilance, racing thoughts, and panic, often centered on the baby's safety. Postpartum depression is dominated by anhedonia, hopelessness, and difficulty bonding. The two frequently co-occur, but the symptom profiles, screening tools, and most of the existing research are different. Most of the medication evidence base, including brexanolone and zuranolone, is on postpartum depression, not postpartum anxiety.

Ketamine for postpartum anxiety: a careful conversation with your OB first

Q: Is ketamine FDA-approved for postpartum anxiety?

No. Brexanolone (Zulresso) and zuranolone (Zurzuvae) are FDA-approved for postpartum depression specifically, not postpartum anxiety. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. None of these medications carries a postpartum-anxiety label. Any use of ketamine for postpartum anxiety is off-label and should be a coordinated decision with your OB or perinatal psychiatrist.

Postpartum anxiety and postpartum depression are not the same condition

Postpartum anxiety is the most common perinatal mental health condition you have probably never heard discussed in the discharge paperwork. Estimates put its prevalence at roughly 15 to 20 percent of new mothers, which is higher than the rate for postpartum depression. The two conditions overlap, but they are not the same. Postpartum anxiety is dominated by intrusive worry, hypervigilance, racing thoughts, panic episodes, and a near-constant sense that something terrible is about to happen to the baby. Postpartum depression is dominated by anhedonia, hopelessness, flat mood, and difficulty bonding.

Many women experience both. Many more experience postpartum anxiety alone and never get a clear diagnosis, because the standard postpartum screening tool, the Edinburgh Postnatal Depression Scale, was designed primarily to catch depression. Anxiety can hide in plain sight behind the exhaustion that everyone tells you is normal.

If you are reading this because the worry has become unmanageable, the first step is not ketamine. The first step is a conversation with your OB or your perinatal psychiatrist about where your symptoms fit and what first-line care looks like. Talk to your OB before you talk to us. We mean that.

Why postpartum anxiety is so undertreated

Several forces conspire to keep postpartum anxiety in the shadows. The first is screening: the Edinburgh tool catches depression better than anxiety, and dedicated perinatal anxiety screens are not yet universal. The second is normalization. New parents are told that worry comes with the territory, and women learn to keep intrusive thoughts to themselves out of fear of being judged.

The third force is the research gap. The treatment literature on perinatal mood and anxiety disorders is overwhelmingly weighted toward depression. Brexanolone (Zulresso) and zuranolone (Zurzuvae) are both labeled for postpartum depression, not postpartum anxiety. The implication is not that anxiety is unimportant. The trials simply have not been done, and treatment decisions for postpartum anxiety are made by extrapolating from adjacent data.

What evidence actually applies here

There is no randomized controlled trial of ketamine for postpartum anxiety as a primary diagnosis. So we look at the adjacent literature, and we are clear with patients about which evidence applies and which does not.

The most directly relevant trial of ketamine for anxiety as a target symptom is Glue and colleagues, published in the Journal of Psychopharmacology in 2017. That study enrolled 12 patients with treatment-refractory generalized or social anxiety disorder. Ten of the 12 responded, with anxiolytic effects lasting up to seven days. The sample was small and not postpartum, but it remains one of the few prospective trials targeting anxiety. We treat it as supportive background evidence, not as a green light.

The postpartum-depression literature is more developed. Studies of intravenous ketamine in postpartum depression, including post-cesarean prevention trials, suggest meaningful antidepressant effects in this population. We discuss this in more depth in our companion piece on ketamine for postpartum depression and our overview of postpartum depression treatment options. For postpartum anxiety, this is borrowed evidence, not direct evidence.

The regulatory landscape matters as well. Esketamine (Spravato) was FDA-approved in 2019 for treatment-resistant depression, with an additional indication added in 2020 for major depressive disorder with acute suicidal ideation. Brexanolone (Zulresso) was approved in 2019 specifically for postpartum depression. Zuranolone (Zurzuvae) was approved in 2023 as the first oral medication for postpartum depression. None of these carries a postpartum-anxiety label. Ketamine itself is FDA-approved as an anesthetic; its use for postpartum anxiety is off-label.

The ACOG Committee Opinion on perinatal mental health, updated in 2023 and published in Obstetrics & Gynecology, recommends universal screening for perinatal anxiety and depression and lists cognitive behavioral therapy, interpersonal therapy, and SSRIs or SNRIs as first-line treatments after a careful benefit-risk discussion. ACOG is also clear that treatment of perinatal mood and anxiety disorders is strongly preferred over no treatment when symptoms meet diagnostic threshold. That guidance shapes how we think about ketamine: not as a first move, but as a possible consideration for a narrow group of patients whose treatment-resistant anxiety has not responded to first-line care.

Breastfeeding, infant exposure, and the questions to ask

This is the section where we most need you to defer to your OB and pediatrician, not to us alone.

Ketamine is excreted into breast milk. The available data is limited, the half-lives are relatively short, and many ketamine clinics use a pump-and-discard window of approximately 12 to 24 hours after each infusion to minimize infant exposure. That is a general practice, not a personalized recommendation. The right window for you depends on your dose, your specific protocol, your baby's age and feeding pattern, and the judgment of your pediatrician.

Before any ketamine plan moves forward in a breastfeeding patient, we want to see the following:

Your OB has been consulted and supports the consideration of ketamine for treatment-resistant postpartum anxiety after first-line options have been tried.
Your pediatrician has been informed and has a plan for monitoring the infant if any breastfeeding occurs.
A perinatal psychiatrist has reviewed the case where one is available, particularly for any patient on existing psychiatric medications that may interact with ketamine.
A pump-and-discard plan is in writing, with feeding logistics solved before the first session, not figured out on the day of treatment.
Adequate caregiver coverage for the post-infusion recovery period is in place. A new mother cannot drive home from a ketamine session, and recovery from postpartum anxiety is harder when she is solo-parenting that evening.

None of this is a barrier we are putting up to discourage you. It is the standard of care that allows us to be genuinely helpful instead of moving fast on someone else's timeline. For a deeper read, see our piece on ketamine during pregnancy and breastfeeding.

First-line treatments to try first

For most patients with postpartum anxiety, the first-line ladder looks like this, in line with ACOG guidance:

Cognitive behavioral therapy or interpersonal therapy, ideally with a clinician experienced in perinatal mental health. Therapy alone is sufficient for many patients with mild to moderate symptoms.
SSRIs or SNRIs, prescribed by your OB or psychiatrist with a benefit-risk conversation that includes breastfeeding considerations. Sertraline is commonly chosen during lactation because of its favorable infant exposure profile, but the right medication is a clinical decision your prescriber makes.
Sleep protection. Anxiety symptoms in early postpartum often improve substantially once a sustained block of sleep is restored. This is not a brush-off. It is a real clinical lever, and addressing it can change the entire treatment picture.
Screening and treatment for postpartum depression, which co-occurs with anxiety often enough that missing it is a common reason patients fail to improve.
Brexanolone or zuranolone, which carry FDA approvals for postpartum depression. They are not anxiety medications, but where postpartum anxiety co-occurs with postpartum depression, they may be on the table in your perinatal psychiatry consult.

Ketamine is not a first-line treatment for postpartum anxiety. We will say that as many times as we need to. Where ketamine becomes a reasonable conversation is in the narrower group of patients whose anxiety is severe, persistent, and has not responded to the steps above. For that group, the relevant framing is treatment-resistant anxiety, and the decision is made jointly with the OB and perinatal psychiatry, not by us alone.

Spravato, brexanolone, zuranolone, and the postpartum-depression label

It is worth understanding why the FDA-approved postpartum medications are not postpartum-anxiety medications, because this shapes what your OB will likely suggest first.

Brexanolone (Zulresso) is an intravenous formulation of allopregnanolone, the metabolite of progesterone that drops sharply after delivery. It is approved specifically for postpartum depression and is administered as a continuous 60-hour infusion in a certified setting. The clinical trials measured depression endpoints, not anxiety endpoints.

Zuranolone (Zurzuvae) is the oral cousin of brexanolone. Approved in 2023, it is taken once daily for 14 days and is the first oral medication labeled for postpartum depression. Again, the trials measured postpartum depression, not postpartum anxiety.

Esketamine (Spravato) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. It is not approved for postpartum depression and not approved for postpartum anxiety. We have a fuller comparison in our article on ketamine for anxiety and our broader content on anxiety treatment and depression treatment.

The pattern across these labels is the same: postpartum depression has the dedicated approvals, postpartum anxiety does not, and treatment of postpartum anxiety necessarily relies on extrapolation. Honest framing matters more than enthusiasm here.

What a careful postpartum-anxiety consult at Music City Ketamine looks like

If your OB and perinatal psychiatry team have walked the first-line ladder and your postpartum anxiety has not responded, we are willing to have the consultation. Here is what that looks like in our clinic.

The intake is longer than for most diagnoses. We want to see the screening scores, the medication trials, the therapy history, and the infant feeding plan. We want a release of information so we can talk directly with your OB, your prescribing psychiatrist, and your pediatrician where applicable. If any of those conversations cannot happen, we do not move forward.

For monitoring, Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring, the same continuous pulse oximetry, blood pressure, and heart rate tracking we describe in our safety overview. A CRNA is in the room during the session. Postpartum patients sometimes have lingering hemodynamic changes from delivery, and we treat that as a reason to be more careful, not less.

Cost is straightforward and transparent. Sessions at Music City Ketamine are $475 each. Insurance generally does not cover off-label ketamine use, and we say so up front. We will never push a six-session induction on a patient who is not yet sure she is ready. If a single consult ends with us recommending you stay the first-line course with your OB instead of starting infusions, that is a successful consult.

Treatment of perinatal mood and anxiety disorders is strongly recommended over no treatment, with first-line options including CBT, IPT, and SSRIs or SNRIs after a careful benefit-risk discussion. Universal screening for perinatal anxiety and depression is recommended. — Paraphrased from ACOG Committee Opinion, Obstetrics & Gynecology, 2023

Honest expectations and the off-label disclosure

We will close with the things we want every postpartum patient to hear out loud.

Ketamine is FDA-approved as an anesthetic; its use for postpartum anxiety is off-label. Esketamine is approved for treatment-resistant depression, brexanolone and zuranolone are approved for postpartum depression, and none of these carries a postpartum-anxiety label. Any decision to use ketamine here is an off-label decision made jointly with your OB.
The evidence base is borrowed, not direct. The Glue 2017 anxiety data and the postpartum-depression literature are the closest analogs we have. They support the biological plausibility of a benefit; they do not constitute proof.
Talk to your OB before you talk to us, and again after. If your OB is uncomfortable proceeding, we are uncomfortable proceeding. That is not a workaround we are going to find for you.
Sleep deprivation is its own problem. Many women report meaningful improvement in postpartum anxiety once protected sleep is restored. We would rather see that addressed before you spend money on infusions.
Never start, stop, or change medications on your own. Discontinuing an SSRI during early postpartum carries real risk and should always be a coordinated decision with your prescriber.
Response is not universal. Even in the postpartum-depression and treatment-resistant anxiety literature, not everyone responds. We will not promise a result we cannot deliver.

Postpartum anxiety is real, it is common, and it deserves real treatment. For most women, that treatment is therapy and an SSRI, coordinated with the OB. For a smaller group whose anxiety has not responded to first-line care, ketamine may eventually be part of the conversation. The only responsible way to get there is together with the people already taking care of you and your baby.